Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
Molecular Cancer Therapeutics
|
August 12, 2018
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Heidi M Namløs, Kjetil Boye, Skyler J Mishkin, et al.
Cancer Biology & Therapy
|
February 27, 2020
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Vegar Johansen Dagenborg, Serena Elizabeth Marshall, Sheraz Yaqub, et al.
British Journal of Cancer
|
March 26, 2025
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Desmond Yip, John Zalcberg, Jean-Yves Blay, et al.
Scientific Reports
|
July 4, 2020
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS)
Emanuela Palmerini, Andreas Leithner, Reinhard Windhager, et al.
Eclinicalmedicine
|
April 28, 2025
Genetic predisposition in sarcomas: clinical implications and management
Elizabeth A Connolly, Kjetil Boye, Sylvie Bonvalot, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 11, 2025
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions
Stefania Kokkali, Ana Dolcan, Kjetil Boye, et al.
British Journal of Cancer
|
June 11, 2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
Heikki Joensuu, Annette Reichardt, Mikael Eriksson, et al.
Cancer Treatment Reviews
|
September 22, 2023
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.
Cancer Immunology, Immunotherapy : CII
|
February 13, 2021
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Kjetil Boye, Alessandra Longhi, Tormod Guren, et al.
Ebiomedicine
|
October 14, 2023
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
Maren Høland, Kaja C G Berg, Ina A Eilertsen, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
Molecular Cancer Therapeutics
|
August 12, 2018
Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
Heidi M Namløs, Kjetil Boye, Skyler J Mishkin, et al.
Cancer Biology & Therapy
|
February 27, 2020
Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
Vegar Johansen Dagenborg, Serena Elizabeth Marshall, Sheraz Yaqub, et al.
British Journal of Cancer
|
March 26, 2025
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial
Desmond Yip, John Zalcberg, Jean-Yves Blay, et al.
Scientific Reports
|
July 4, 2020
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS)
Emanuela Palmerini, Andreas Leithner, Reinhard Windhager, et al.
Eclinicalmedicine
|
April 28, 2025
Genetic predisposition in sarcomas: clinical implications and management
Elizabeth A Connolly, Kjetil Boye, Sylvie Bonvalot, et al.
Acta Oncologica (Stockholm, Sweden)
|
June 11, 2025
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions
Stefania Kokkali, Ana Dolcan, Kjetil Boye, et al.
British Journal of Cancer
|
June 11, 2024
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial
Heikki Joensuu, Annette Reichardt, Mikael Eriksson, et al.
Cancer Treatment Reviews
|
September 22, 2023
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
Roelof van Ewijk, Morgane Cleirec, Nikolas Herold, et al.
Cancer Immunology, Immunotherapy : CII
|
February 13, 2021
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Kjetil Boye, Alessandra Longhi, Tormod Guren, et al.
Ebiomedicine
|
October 14, 2023
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
Maren Høland, Kaja C G Berg, Ina A Eilertsen, et al.
Page
of 8